Biotia

Biotia is using genomics and AI to fight infectious diseases. Surveillance, rapid diagnostics and prevention is important to stop the spread of infectious diseases. Biotia is working with clinicians and researchers to leverage high-complexity tests and AI for rapid precision infectious disease discovery to guide patient treatment and improve health outcomes. To attain this, Biotia is using a hybridization capture-based next-generation sequencing assay as a robust alternative to PCR that deals with rapidly mutating organisms leading to less drop-outs. Biotia has received FDA emergency use authorization to use their sequencing-based COVID-19 test that enables accurate surveillance of SARS-CoV-2 variants of concern with an assay resilient to genomic variation.

Jobs: